{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-013074","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2025-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.487100+00:00","generated_at":"2026-05-17T06:54:30.907776+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MAIA reports positive THIO-101 Phase 2 data: PFS 5.6 mo, OS 17.8 mo in 3L NSCLC","bullets":["Estimated median PFS of 5.6 months (180 mg dose) vs 2.5 months standard of care in third-line NSCLC.","Estimated median OS of 17.8 months (95% CI lower bound 12.5 months), consistent with prior readout.","2 patients completed 33 cycles, suggesting extended dosing and tolerability for ateganosine.","Phase 2 expansion trial began enrolling patients in July 2025 to further validate efficacy."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-013074","json":"https://secwatch.observer/filing/0001493152-25-013074.json","markdown":"https://secwatch.observer/filing/0001493152-25-013074.md","text":"https://secwatch.observer/filing/0001493152-25-013074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225013074/0001493152-25-013074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000149315225013074/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:54:30.907776+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}